Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Epitalon and Thymulin — mechanism, side effects, legal status, and pricing.
Epitalon (also Epithalon, AEDG) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology as a synthetic analog of the bovine pineal extract Epithalamin. It is a research-only bioregulator — not FDA-approved and not included in any major Western clinical guideline.
Thymulin is a zinc-dependent nonapeptide (pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) secreted by thymic epithelial cells, originally isolated by Bach and colleagues in the 1970s as 'facteur thymique sérique' (FTS). It is NOT the same compound as Thymalin (a Russian bovine thymus extract) or Thymosin alpha-1 (a separate 28-amino-acid thymic peptide). Thymulin is not FDA-approved; use is research/investigational only.
Epitalon
Thymulin
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Epitalon
Thymulin
COA corpus from Disclosed Labs — independently tested batches only.
Epitalon
87
COAs
99.3%
Avg purity
14
Labs
Thymulin
5
COAs
99.5%
Avg purity
4
Labs
The evidence base is dominated by the Khavinson group. A 2003 paper in Bulletin of Experimental Biology and Medicine (Khavinson, Bondarev, Butyugov; PMID 12937682) reported telomerase activation and telomere elongation in cultured human fetal fibroblasts. Additional Khavinson-group papers and reviews (e.g. 'Peptides and Ageing,' PMID 12374906) describe melatonin-rhythm normalization and claimed geroprotective effects in elderly Russian patients treated with epithalamin or epitalon in open-label / small-cohort studies over 6–12 year follow-up. These clinical studies have significant methodological limitations (open-label design, single-center, limited controls) and have NOT been independently replicated in rigorous Western controlled trials. There are no Phase 2/3 trials, no FDA approval, and no inclusion in Western clinical guidelines. Grey-market dosing of 5–10 mg SubQ daily for 10–20 day cycles, 1–2 times per year, is not clinically validated for any endpoint.
Key references
Bach and Dardenne originally characterized FTS/thymulin and its absolute zinc dependency (Bach & Dardenne, Med Oncol Tumor Pharmacother 1989, PMID 2657247). Prasad et al. (J Clin Invest 1988, PMID 3262625) showed that serum thymulin activity falls in human zinc deficiency and recovers with zinc supplementation. Mocchegiani et al. (Int J Immunopharmacol 1995, PMID 8582782) demonstrated partial reversal of thymic involution with zinc in aged mice. Dardenne & Pleau reviewed zinc-thymulin interactions (Met Based Drugs 1994, PMID 18476235). Safieh-Garabedian et al. (Br J Pharmacol 2002, PMID 12110619) reported analgesic/anti-inflammatory activity of a thymulin-related peptide in rats. There are NO large, modern RCTs of exogenous thymulin in humans; clinical use is experimental.
Epitalon (Cosmetic) and Thymulin (Immune) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references
Disclosed Labs